CAV1 and prostate carcinoma: Concurrently, a loss of stromal CAV1, particularly affecting cancer associated fibroblasts (CAF), could be observed, which correlated with tumor progression, therapy resistance, and predicted adverse outcome, e.g. in breast and prostate cancer (25, 37–40).